CLAIMS

What is claimed is:

1. Use of an effective amount of an anti-CGRP antibody in the manufacture of a medicament for acute treatment of migraine in a patient, wherein the patient has a headache and wherein said medicament is to be administered to said patient within 30 hours of headache onset, preferably within 24 hours of headache onset,

> wherein the anti-CGRP antibody is to be administered in an amount of 100 mg or 300 mg, via intravenous infusion, and
>
> wherein said anti-CGRP antibody comprises the light chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 224; SEQ ID NO: 226; and SEQ ID NO: 228, respectively and heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 204; SEQ ID NO: 206; and SEQ ID NO: 208, respectively.

2. The use of claim 1, wherein said anti-CGRP antibody administration begins within 18 hours, within 12 hours, within 6 hours, within 5 hours, within 4 hours, within 3 hours, within 2 hours, or within 1 hour of headache onset, such as between 1-6 hours from headache onset.

3. The use of any one of the foregoing claims, wherein said patient is free from the most bothersome symptom (MBS) at 2 hours post-completion of administration or infusion.

4. The use of any one of the foregoing claims, wherein said administration improves one or more of the following: time to pain relief; time to pain freedom; headache pain freedom at 2 hours with sustained headache pain freedom for 24 and 48 hours post completion of infusion; use of rescue medication by 24 hours and by 48 hours post completion of infusion; absence of photophobia at 2 hours post completion of infusion; absence of phonophobia at 2 hours post completion of infusion; absence of nausea at 2 hours post completion of infusion; change from baseline in Headache Impact Test (HIT-6) at Week 4; or change from baseline in Migraine Treatment Optimization Questionnaire-6 (MTOQ-6) at Week 4.

5. The use of any one of the foregoing claims, wherein said anti-CGRP antibody comprises the variable light chain polypeptide of SEQ ID NO: 222 and the variable heavy chain polypeptide of SEQ ID NO: 202.

6. The use of any one of the foregoing claims, wherein said anti-CGRP antibody comprises the light chain polypeptide of SEQ ID NO: 221 and the heavy chain polypeptide of SEQ ID NO: 201 or SEQ ID NO: 566.